Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.

CONCLUSION: In this study, whatever the criteria, only 24.2% of patients with SID who received IgRT met EMA recommendations, which suggests a misuse of IgRT in SID.
PMID: 32289463 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - April 10, 2020 Category: Cancer & Oncology Authors: Legendre P, Chahwan D, Marjanovic Z, Vignon M, Hermine O, Lortholary O, Morelle G, Darrodes M, Kahn JE, Ouzegdouh M, Chaibi P, Montestruc F, Caumont-Prim A, Le Jouan M, Hassani Y, Godeau B, Durand-Zaleski I, Mouthon L Tags: Clin Immunol Source Type: research